Risk of second primary malignancies in a population-based study of adult patients with essential thrombocythemia

Table 5 Risk of secondary primary malignancies based on age at the time of diagnosis of essential thrombocythemia

SPM	Overall SIR (95%CI)	SIR for age group, 18-60 yr (95%CI)	SIR for age group, > 60 yr (95%CI)
All sites	1.26 (1.09-1.45)1	1.78 (1.31-2.36)1	1.15 (0.98-1.35)
Solid tumors	1.15 (0.98-1.35)	1.75 (1.27-2.35)1	1.03 (0.85-1.23)
Colorectal	0.66 (0.34-1.15)	1.33 (0.27-3.88)	0.56 (0.26-1.07)
Lungs/bronchus	1.31 (0.89-1.86)	2.36 (0.86-5.13)	1.19 (0.77-1.75)
Breast	1.06 (0.68-1.58)	1.08 (0.40-2.35)	1.06 (0.63-1.67)
Prostate	1.11 (0.71-1.65)	1.91 (0.82-3.76)	0.92 (0.52-1.49)
Kidney	2.40 (1.15-4.42)1	2.32 (0.28-8.37)	2.42 (1.05-4.78)1
Lymphoma	1.59 (0.82-2.78)	1.72 (0.21-6.23)	1.57 (0.75-2.88)
Leukemia	3.78 (2.2-6.05)1	3.74 (0.45-13.51)	3.78 (2.12-6.24)1
AML	7.74 (3.71-14.24)1	12.73 (1.54-45.98)1	7.06 (3.05-13.90)1

¹Indicates a statistically significant value. AML: Acute myeloid leukemia; SIR: Standardized incidence ratio; SPM: Second primary malignancies.